Purpose: High-dose chemotherapy and autologous stem cell transplantation(ASCT) has been used for clinically aggressive non-Hodgkin's lymphoma. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation, Ara-C and melphalan (TAM) for clinically aggressive NHL. Material and Methods : Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI of 12 Gy over 3 days, 9 g/m2 Ara-C and 100 mg/m2 melphalan followed by ASCT. Patients who respond to first line chemotherapy and achieved complete remission (CR), or in first sensitive relapse were defined as having less advanced disease, while others were defined as having more advanced disease. Results : Objective responses were obtained in 24 of 31 patients (77.4 %), CR in 19 patients (61.3 %) and PR in 5 (16.1 %) patients. The median follow-up time was 28 months (range 1-62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3 % and 47.3 %, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3 % and 22.5 %, respectively (P=0.006). Early treatment-related mortality occurred in 3 (9.7 %) patients. Of the 31 total patients, 15 (48.4 %) developed grade 3 mucositis, 21 (67.4 %) developed neutropenic fever. Conclusions : The modified TAM conditioning regimen and ASCT appeared to be a feasible treatment for clinically aggressive NHL, particularly in patients with less advanced disease.
